Evaluation of Antibody Responses in Hemodialysis Patients, Peritoneal Dialysis, Kidney Transplant Recipients and Normal Subjects after Administration of 23-Valent Pneumococcal Polysaccharide Vaccine by Argani, Hasan & Rostamiasl, Ali
                                                                                                                           Novelty in Biomedicine 




Evaluation of Antibody Responses in Hemodialysis Patients, 
Peritoneal Dialysis, Kidney Transplant Recipients and Normal 




Hasan Argani1, Ali Rostamiasl1 
 
1 Renal Department, Modarres hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
 
Received: 06 June, 2019; Accepted: 09 November, 2019 
Abstract 
Background: Pneumococcal vaccines are recommended in patients with immune deficiencies such as kidney 
transplant recipients and dialysis subjects. Streptococcus pneumoniae is an agent of pneumonia, meningitis, 
important morbidities and mortality in such patients. The purpose of this study was to evaluate and compare the 
antibody responses in hemodialysis patients, peritoneal dialysis, kidney transplant recipients and normal subjects 
after administration of 23-valent pneumococcal polysaccharide vaccine (PPV23). 
Materials and Methods: The present randomized clinical trial was conducted on 162 subjects including 57 
hemodialysis patients, 29 peritoneal dialysis patients, 48 kidney transplant recipients, and 28 healthy controls. 
The participants received a single-dose pneumococcal vaccine (Pneumovax 23) of 0.5 ml in the upper limb 
muscle. The efficacy of vaccination was evaluated by measuring the antibody response to the entire vaccine. 
Serum samples were collected before, one and six months after vaccination. 
Results: The levels of IgG pneumococcal antibodies at pre-vaccination periods, one and six months after 
vaccination were 11.6±1.52 IU/ml, 14.98±1.98 IU/ml and 14.87±0.66 IU/ml in kidney transplant recipients, 
12.03±1.93 IU/ml, 15.26±0.49 IU/ml and 14.3±0.72 IU/ml in hemodialysis patients, and 11.5±1.55 IU/ml, 
15.2±1.81 IU/ml, and 14.2±1.7 IU/ml, respectively. The serum antibody level was significantly higher in 
kidney transplant recipients than in both dialysis groups after six months of vaccination (p=0.029). 
Conclusion: We found that patients with renal failure respond to pneumococcal vaccination in hemodialysis and 
kidney transplantation. However, they lost their serum antibodies within six months of vaccination. Determining 
the protective level for serum IGG and IGG2 in these patients helps us to follow up on these patients more 
precisely in order to re-vaccinate when the protective level of serum antibody is broken.  
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Pneumococcal infection is one of the major causes of 
morbidity and mortality in the world1. Pneumonia, 
bacteremia, sepsis, and meningitis are the most 
common manifestations of invasive pneumococcal 
disease; the hematogenous spreading of the bacteria 
causes a minimally-invasive middle ear infection, 
Evaluation of Antibody Responses in Hemodialysis Patients, Peritoneal Dialysis, Kidney …                Argani and Rostamiasl 
NBM 37 Novelty in Biomedicine 2020, 1, 36-44 
sinusitis, and chronic bronchitis2. In contrast to 
invasive infections, non-invasive infections are less 
severe but more prevalent. Although all age groups are 
affected, there is a high prevalence of pneumococcal 
infection in adolescents and the elderly. In addition, 
people with various chronic illnesses and immune 
deficiencies are at risk3. The pneumonia is a common 
infection in dialysis patients and with an incidence rate 
of 21% per year in a study of 289,000 hemodialysis 
patients. More than 80% of dialysis patients with 
pneumonia have no known microbial agents, and 
approximately 50% of such patients will die within 12 
months4. Although the proportion of pneumococcal 
pneumonia is unclear in the incidence and mortality of 
pneumonia in the dialysis patients, the administration 
of pneumococcal vaccine seems to be logical in 
reducing this high mortality rate5. As one knows, the 
uremic environment in dialysis patients and the use of 
immunosuppressive drugs in the transplant patients 
cause immune deficiency and contribute to reducing 
the antibody response and host serum changes to 
vaccination6. As a result, the level of adherence and 
willingness to vaccinate is reduced in these patients. 
For example, in a study on 683 hemodialysis patients, 
only 44% received the pneumococcal vaccine7, which, 
of course, seems to be much less in our country, Iran. 
Therefore, this low tendency to vaccination appears to 
be due to the lack of information on the pneumococcal 
vaccine in these patients8. Although a decrease in the 
protective level of the antibody has been reported after 
pneumococcal vaccination in some studies9-11, 
multiple studies have shown that vaccination is 
effective in this group of patients12,13. 
Therefore, given the high risk of infection in these 
patients and the probability of mortality, and since this 
topic has never been investigated in the country so far, 
the current study was conducted to evaluate the 
antibody response in hemodialysis patients, peritoneal 
dialysis, kidney transplant recipients and normal 
subjects after the administration of PPV23 (23-valent 
pneumococcal polysaccharide vaccine). 
Methods 
This clinical trial was performed on 105 hemodialysis 
patients, peritoneal dialysis subjects, kidney transplant 
recipients and normal people referred to the 
hemodialysis center of Modarres Hospital and Kidney 
Transplantation Clinic and Shafa Clinic in Tehran. The 
sample size in this study was calculated based on the 
study conducted by Monika Lindemann et al.14, who 
only compared the antibody titer against pneumococci 
in kidney transplant recipients before and after the 
vaccination and used median and IQR (interquartile 
range) to obtain sample size. In this approach, the 
assumption was that the distribution of data was normal 
and the standard deviation was considered to be 
approximately 3.4 IQR. Considering the small sample 
size, 10% was added to the final sample size for highly 
skewed distributions. Accordingly, the sample size was 
calculated to be 105. In this study, the patients were 
divided into four groups including 20 peritoneal 
dialysis patients, 40 hemodialysis patients, 20 kidney 
transplant patients, and 25 healthy subjects. Exclusion 
criteria were the lack of cooperation of the patient in the 
timely attendance and unwillingness to participate in 
the study and taking samples. A blood sample was taken 
before the vaccination from all eligible subjects by 
observing ethical considerations, and then demographic 
information and follow-up profiles were recorded. A 
single-dose of PPV23 was injected at zero time and the 
next blood samples were taken one and six months later. 
The serum blood samples of the patients were analyzed 
for pneumococcal antibodies in the months 0, 1 and 6 
months after vaccination with Human Anti-
Pneumococcal CPS23 IgG ELISA Kit in a 
Pathobiology Laboratory in Tabriz city. 
Attained data were analyzed by SPSS version 21 
software using the Kolmogorov-Smirnov test to 
evaluate the normal distribution of data, Mann-Whitney 
and Log Transformation test to assess nonparametric 
variables, ANCOVA test to study the effect of 
confounding factors and the difference in the baseline 
values of metabolic parameters and others between the 
groups. In all stages, P<0.05 was considered as a 
significance level. 
Results 
In this study, 162 people were included in the study. 
The minimum age of the person entering the study was 
21 years and the maximum age was 74 years. The study 
examined 28 healthy subjects (17.3%), 29 peritoneal 
dialysis patients (17.9%), 48 kidney transplant 
recipients (29.6%) and 57 hemodialysis subjects 
(35.2%). The mean age of the subjects in the study was 
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46.7±11.43 years. The ANOVA test showed a 
statistically significant difference in the mean age 
between the participants in the study (P=0.01). 
The results of Tukey's post hoc analysis showed no 
significant difference between the control group and 
the peritoneal dialysis group (P=0.17), but the 
significant difference between the control group and 
the transplant group (P=0.013) and the hemodialysis 
group (P=0.012). 
The study population consisted of 115 men (71%) and 
47 women (29%). The results revealed no statistically 
significant difference in the mean age between women 
and men participating in the study. 
In evaluating the concentration of PPV23-derived 
antibodies in the studied groups, the results showed that 
the distribution of this antibody in the sample was 
normal in the first measurement and sample distribution 
was non-normal in the remaining two doses (P<0.05). 
The mean, standard deviation, median, and Interquartile 
range of these variables are presented in Table 2. 
Table 2 exhibits that one-way ANOVA showed no 
difference in antibody concentration between different 
 
Figure 1. Gender distribution of the participants in different groups under study. 
 
 
Figure 2. Distribution of antibody concentration variable in the second dose for all subjects. 
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groups at zero time (P=0.3). Moreover, the results of 
the nonparametric Kruskal-Wallis test indicated that 
there was no difference between the mean 
concentrations of PPV23-derived antibodies after one 
month of vaccination. 
In examining the difference in the antibody 
concentration after six months of vaccination, the 
results showed that there was a significant difference 
between the groups and this difference was between 
the peritoneal dialysis, kidney transplant and 
hemodialysis groups (P=0.029). 
The repeated-measures ANOVA was used to evaluate 
the effect of vaccination on the serum antibody level in 
comparison with the control group in the first approach. 
Figure 4 displays the trend of changes in the serum 
antibody levels secreted in all four groups. 
As shown in Figure 3, an increase in serum antibodies 
occurred after a month of vaccination, which was 
accompanied by a slight decrease in the next five 
months. Figure 4 displays the process of separate 
changes in each group. 
Further, in examining the significant difference 
between the anti-PPV23 antibody concentrations over 
time, the results of repeated measures ANOVA by 
 
Figure 3. Changes in serum anti-streptococcal antibodies in subjects participating in the study. 
 
 
Figure 4. The trend of changes in the level of anti-pneumococcal antibodies 23 in different groups. 
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comparing the age of the participants in the study 
showed that the changes in the serum level of anti-
pneumococcal antibodies in all four groups were 
associated with a significant decrease (P<0.001) and 
this change was the same for all studied groups and 
there was no significant difference in immunogenicity 
of the vaccine between different groups (P=0.82). In 
the fitted models, the interaction between the factor 
studied (serum antibody level) and the studied groups 
were significant, indicating a different 
immunogenicity effect of the vaccine at different 
times. In the second approach, the GEE analysis based 
on distribution-free was used to confirm the findings 
of repeated measures ANOVA. This analysis also 
showed no group effect on immunogenicity from the 
vaccine. Table 3 represents the results of this model.  
The results of Table 3 show that the antibody titer in 
the peritoneal dialysis group was decreased by the 
coefficient of -0.16 in comparison with the control 
group, and the other two groups with the coefficients of 
0.03 and 0.09 were more than the control group; 
however, not all of the above items were statistically 
significant. 
In this study, the correlation between serum Tacrolimus 
level and antibody level before vaccination and six 
months after vaccination was investigated. The results 
of this study are shown in Table 4. According to the 
results of this table, there was no significant 
relationship between antibody level and drug level 
before and after the intervention. 
Discussion 
The patients with chronic renal failure are at high risk 
for infections caused by Streptococcus pneumoniae. 
This defect can be due to the reduction of antibody 
response to these polysaccharide antigens in such 
Table 1: Statistical comparison of the age between the participants in the study. 
Group Frequency Mean ± SD P-value 






Blood dialysis 57 46.7±11.4 
 
 Table 2: Mean, standard deviation, median and interquartile range of antibody concentration in different groups at 
zero, one month and six months after vaccination. 
Time Group Mean ± SD Median (IQR) P-value 
zero 
Control 12±1.32 12.1 (11.2-13.1) 
0.30 
Peritoneal Dialysis 11.5±1.55 11.8 (11-12.45) 
Kidney transplant 11.6±1.52 11.7 (10.6-12.9) 
Blood dialysis 12.3±1.93 12.1 (11.1-13.2) 
Total 11.82±1.66 12 (11.1-13) 
one month 
Control 14.68±2.14 15.35 (14.6-15.7) 
0.36 
Peritoneal Dialysis 15.2±1.81 15.45 (15.2-15.9) 
Kidney transplant 14.98±1.98 15.4(15-15.9) 
Blood dialysis 15.26±0.49 15.4 (15.1-15.5) 
Total 15.07±1.16 15.4 (15.1-15.7) 
six months 
Control 14.5±0.97 14.7 (14-15.2) 
0.015 
Peritoneal Dialysis 14.2±1.7 14.45 (14.05-14.9) 
Kidney transplant 14.87±0.66 15 (14.6-15.3) 
Blood dialysis 14.3±0.72 14.3 (14-14.8) 
Total 14.5±1.01 14.7 (14.1-15.1) 
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patients15-18. Although immunization of these patients 
with pneumococcal polysaccharide vaccine has been 
suggested19, there are rare reports of evaluating this 
vaccine in patients with chronic renal failure20. 
Similarly, the efficacy of the vaccine in these patients 
is not well defined20,21. The appropriate response to 
antibodies and pneumococcal antigens in patients with 
chronic renal failure can highlight the importance of 
vaccination in protecting against pneumococcal 
infections, and thus they may be protected against 
pneumococcal infections. 
In evaluating the concentration of PPV23-derived 
antibodies in the studied groups, the results 
demonstrated that the distribution of this antibody in 
the sample was normal in the first measurement and 
non-normal in the other two doses. One month after 
vaccination, there is no difference between the mean 
concentrations of PPV23-derived antibodies, but the 
antibody level increased with respect to the first 
measurement, in line with the results of the study by 
Fuchschuber et al.20. The results showed that 83% of 
patients with chronic renal failure developed 
protective antibodies against pneumococcal antigens 
four weeks after immunization. This finding from the 
present study reveals that we can identify those with 
the poor responses that are more at risk for 
pneumococcal infections by measuring antibody 
dilution against pneumococcal antigens after 
vaccination. Concerning the difference in the antibody 
concentrations after six months of vaccination, there 
was a significant statistical difference between the two 
groups. This difference was between peritoneal dialysis 
with kidney transplant groups as well as hemodialysis 
with kidney transplant groups; so that it was higher in 
kidney transplant group than the other two groups but 
no significant difference exists between dialysis and 
kidney transplant groups with the control group. 
After a month of vaccination, an increase in serum 
antibodies occurred, with a slight decrease over the next 
five months. The changes in the level of anti-
pneumococcal antibodies in all four groups were 
associated with a significant reduction in the statistical 
significance and this change for all groups was similar 
and there was no significant difference in the 
immunogenicity of the vaccine between different 
groups. These data are consistent with the findings from 
the study of Ambrosiono et al.22 that showed that 
children with recurrent infections after pneumococcal 
vaccination (containing 14 strains of bacteria) produced 
normal levels of IgG against pneumococcal antigens. In 
fact, the results of our study indicated the PPV23 
immunization in patients with chronic renal failure. 
Additionally, the data of anti-pneumococcal IgG titers 
after vaccination in the patients with normal specific 
Table 3: The results of the GEE model for investigating the effects of different groups on the immunogenicity of the 
anti-pneumococcal antibodies 23. 
Variable  Class Coefficient P-value 
Group 
Control - - 
Peritoneal Dialysis 
-0.16 (-0.84-0.52) 0.65 
Kidney transplant 
0.03 (-0.55-0.6) 0.92 
Blood dialysis 0.09 (-0.41-0.59) 0.72 
Age Age -0.006 (-0.015-0.014) 0.93 
Sex 
Male - - 
Female 0.07 (-0.37-0.51) 0.75 
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antibody responses are in line with the findings of 
Dengler23, which examined the immune response in 
the transplant recipient by the administration of the 
pneumococcal vaccine. The follow up exhibited that 
the patients with poor antibody response to the 
pneumococcal vaccine were infected with respiratory 
pneumococcal infections more than patients in Group 
2 (patients with normal antibody response). These 
findings confirm previous studies, which showed that 
patients with chronic renal failure are more 
susceptible to recurrent respiratory infections24-27. 
According to the findings of this study, there was a 
significant relationship between the serum antibody 
level and the studied groups, highlighting the different 
immunogenicity of the vaccine at different times. The 
rate of increasing antibody level after vaccination and 
the rate of decreasing serum level after month 1 to 
month 6 in renal patients was higher than that in the 
control group. Limited studies exist about the efficacy 
of the pneumococcal vaccine in patients with renal 
failure. A study by Simberkoff on patients who were 
at higher risk for multiple infections, including those 
with renal failure, suggested that injections of 
pneumococcal polysaccharide vaccine in the patients 
with renal failure in the prevention of pneumonia or 
bronchitis have been associated with poor effects, or 
the effect of the vaccine on immune system induction 
has been too weak28. Case/control studies on patients 
with chronic infections indicated the preventive effect 
of the vaccine on the occurrence of pneumonia29. 
Other related studies have shown that hemodialysis 
patients, as well as kidney transplant recipients who 
produce antibodies at normal levels with 
pneumococcal vaccine, were advised to vaccinate and 
even booster to induce immunity12. On the other hand, 
the booster will be even ineffective in patients with 
poor response30-31. Studies have demonstrated that pure 
polysaccharide antigens induce type 2 antibodies (non-
T cell-dependent), and these antigens do not stimulate 
memory B cells. However, the booster is unable to 
enhance the production of these antibodies in the 
secondary response. Therefore, the injection of a 
conjugate vaccine (a bacterial polysaccharide capsule 
conjugated with vector proteins) may improve the 
immune response in patients with poor response. Zielen 
et al. were able to enhance the antibody production rate 
in immunocompromised patients by administering the 
pneumococcal conjugate vaccine (containing seven 
bacterial strains) before injection of a pneumococcal 
vaccine containing 23 bacterial strains32. 
Conclusion 
The results obtained from the present study indicated 
that the kidney failure patients undergoing 
hemodialysis and renal transplantation have a good 
response to pneumococcal immunization, but they have 
a rapid drop in serum antibodies within six months of 
vaccination. Knowledge of the protective levels of 
antibodies in these patients will help to make 
revaccinations more accurate and when necessary, 
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